Pick up an Ypsomed injection pen or autoinjector and the first things you notice are likely the technology, design, or ease of use. These are the tangible outcomes of Ypsomed’s purpose: making self-care simpler and easier.
What is less apparent, but equally essential, is the framework that allows such innovations to become reality. Every new idea must navigate a complex landscape of global regulatory requirements before it can safely reach patients. As such, Regulatory Affairs plays an indispensable role in enabling and supporting innovation. It is the part of drug delivery device development that rarely makes headlines. Yet it ensures promising concepts don’t remain sketches but develop into trusted solutions that meet the highest standards of safety and performance. If innovation is the visible face of device delivery development, regulatory is the compass that keeps it on course.
Stefanie Stark and Sandra Schaerer-Lickova of Ypsomed highlight how regulatory strategy enables ideas to become solutions, supports development through the product lifecycle, and helps ensure that patients worldwide obtain safe and timely access.
Ypsomed’s Core Values and Their Regulatory Relevance
In today’s drug delivery environment, pace and complexity are increasing. The growth of innovative biologics, fast-emerging biosimilars, and rapid penetration of GLP-1 agonists into new indications are just a few examples of how therapy areas, molecules, and patient needs are all evolving.
There is a rising demand for devices that enable outpatient and, in particular, at-home care. This is partly driven by more engaged patients who expect user-friendly, sometimes connected solutions and a seamless experience with their medication.
Simultaneously, regulatory priorities are evolving in step with geopolitical shifts, creating a growing trend toward mandatory localisation, more rigorous documentation, and enhanced supply chain visibility across different markets.
In this rapidly evolving environment, Ypsomed’s four strategic pillars serve as guiding principles:
• a commitment to innovation,
• standardised yet highly adaptable device platforms,
• operational excellence, and
• a deep sense of responsibility.
Over the past decades, these values have enabled Ypsomed to establish a mature and proactive approach to regulatory partnership. Rather than simply reacting to new health authority requirements or waiting for the new guidelines to emerge, Ypsomed integrates regulatory expertise one of several guiding factors throughout development: from innovation to early platform design and through the product lifecycle. This philosophy ensures that innovation is consistently aligned with both regulatory expectations and the evolving needs of patients and pharma partners.
